Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
It’s official: Roche is a Car-T player
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Nkarta: at least as good as Fate, at a tenth of the price
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.